Sotorasib and adagrasib each received FDA breakthrough designation for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation, and sotorasib has now received marketing authorization in the US and other countries for the treatment of certain patients with KRAS G12C NSCLC13. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.